Johnson & Johnson launches PERSIGMA head-to-head pulsed field ablation trial in persistent AFib

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Johnson & Johnson initiated PERSIGMA, randomized controlled trial designed to generate head-to-head evidence on pulsed field ablation platforms in persistent atrial fibrillation.
  • Trial will enroll up to 466 patients across 50 sites, comparing investigational VARIPULSE Pro with FARAPULSE.
  • Primary readouts will focus on safety events, effectiveness measured as freedom from arrhythmia recurrence during follow-up.
  • Early procedural experience from one of first PERSIGMA cases will be presented at Heart Rhythm 2026 on April 24.
  • Study adds comparative data intended to support product positioning for Johnson & Johnson electrophysiology portfolio as pulsed field ablation adoption expands into more complex patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.